New Home Care Guidelines by Health Ministry for COVID19 Patients
In this lesson, Dr Mahipal Rathore talks about the New Home Care Guidelines by Health Ministry for COVID19 Patients in Home Isolation. It is very important for the students and General Public at large regarding the management of pandemic.
India Fights With COVID - A Sonu Sood Initiative...
India Fights With COVID - A Sonu Sood Initiative
OUR SERVICES ARE FREE. नि:शुल्क सेवा। pediatric heart surgeries: 02067083686.
👉 https://t.me/IndiaFightsWithCovid
👉 https://www.facebook.com/ActorSonuSood
👉 https://twitter.com/SonuSood
COVID-19 SOS: Here's a list of resource updates:-
Click Here
👇
https://twitter.com/i/events/1385596085192691712
Follow this page for the latest live conversation of the ground efforts as doctors, hospital workers, influencers and concerned citizens across India amplify the latest on the COVID-19 pandemic.
Third wave of Covid-19 will hit children in a big way:-
Virologist Dr. V Ravi has warned that the third wave of Covid-19 will hit children in a big way and it is time for both the Centre and state governments to chalk out strategies and gear up to handle the situation between October and December.
Covid-related questions and answers:-
The Ministry of Health and Family Welfare is an Indian government ministry charged with health policy in India. It is also responsible for all government programs relating to family planning in India. The Minister of Health and Family Welfare holds cabinet rank as a member of the Council of Ministers.
For Any kind of questions, you could refer to the given link-
https://www.uptodate.com/contents/covid-19-questions-and-answers
Do kids get covid?
Children & teens can get COVID-19.
What you need to know...
While fewer children have been sick with COVID-19 compared to adults, children can be infected with the virus that causes COVID-19, can get sick from COVID-19, and can spread the virus that causes COVID-19 to others. Children, like adults, who have COVID-19 but have no symptoms (“asymptomatic”) can still spread the virus to others.
Most children with COVID-19 have mild symptoms or have no symptoms at all. However, some children can get severely ill from COVID-19. They might require hospitalization, intensive care, or a ventilator to help them breathe. In rare cases, they might die.
CDC and partners are investigating a rare but serious medical condition associated with COVID-19 in children called Multisystem Inflammatory Syndrome in Children (MIS-C). We do not yet know what causes MIS-C and who is at increased risk for developing it. Learn more about MIS-C.
Babies under 1 year old might be more likely to have severe illness from COVID-19. Other children, regardless of age, with the following underlying medical conditions might also be at increased risk of severe illness compared to other children:
- Asthma or chronic lung disease
- Diabetes
- Genetic, neurologic, or metabolic conditions
- Sickle cell disease
- Heart disease since birth
- Immunosuppression (weakened immune system due to certain medical conditions or being on medications that weaken the immune system)
- Medical complexity (children with multiple chronic conditions that affect many parts of the body, or are dependent on technology and other significant supports for daily life)
- Obesity
This list does not include every underlying condition that might increase the risk for severe illness in children. As more information becomes available, CDC will continue to update and share information about risk for severe illness among children.
If your child has an underlying condition, make sure to discuss your child’s potential for getting very sick with their healthcare provider. Symptoms of COVID-19 are similar in adults and children and can look like symptoms of other common illnesses such as colds, strep throat, or allergies. The most common symptoms of COVID-19 in children are fever and cough, but children may have any of these signs or symptoms of COVID-19:
- Fever or chills
- Cough
- Nasal congestion or runny nose
- New loss of taste or smell
- Sore throat
- Shortness of breath or difficulty breathing
- Diarrhea
- Nausea or vomiting
- Stomachache
- Tiredness
- Headache
- Muscle or body aches
- Poor appetite or poor feeding, especially in babies under 1 year old
What you can do
Pay particular attention to:
- Fever (temperature 100.4 °F or higher)
- Sore throat
- New uncontrolled cough that causes difficulty breathing (for a child with chronic allergic/asthmatic cough, see if there is a change from their usual cough)
- Diarrhea, vomiting, or stomachache
- New onset of severe headache, especially with a fever
If your child or you were around someone who has COVID-19, someone from the health department may contact you for contact tracing. Speak with them and follow their advice.
Take steps to protect your child if you are sick and slow the spread of COVID-19.
To learn more about how to protect yourself from the virus that causes COVID-19 visit the How to Protect Yourself and Others page.
If your child has symptoms of COVID-19:
- Keep your child home.
- Consider whether your child needs to see a healthcare provider and be tested for COVID-19. CDC recommends all people with symptoms of COVID-19, including children, get tested. CDC has a Coronavirus Self Checker available in its website, which may help you make decisions about seeking medical care for possible COVID-19.
- Protect yourself from COVID-19 while caring for your sick child by wearing a mask, washing your hands frequently, monitoring yourself for symptoms for COVID-19, and using other preventive measures.
- Notify your child’s school that your child is sick. Also inform the school if your child has had a COVID-19 test and what the result is, if available.
- Review your child’s school (or other childcare facility) policies related to when a child who has been sick can return.
- Bring your child back to school or other in-person activities only after they can safely be around others.
Do not delay seeking emergency care for your child because you are worried about the spread of COVID-19. Emergency departments have infection prevention plans to protect you and your child from getting sick with COVID-19 if your child needs emergency care.
If your child is showing any of these emergency warning signs, seek emergency medical care immediately.
- Trouble breathing
- Pain or pressure in the chest that doesn’t go away
- New confusion
- Can’t wake up or stay awake when not tired
- Pale, gray, or blue-colored skin, lips, or nail beds, depending on skin tone
This list does not include all possible symptoms.
Call your child’s healthcare provider for any other symptoms that are severe or concerning to you.
Source:- https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/children/symptoms.html
How COVID-19 started in India?
The COVID-19 pandemic in India is part of the worldwide pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first case of COVID-19 in India, which originated from China, was reported on 30 January 2020.
The COVID-19 pandemic in India is part of the worldwide pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first case of COVID-19 in India, which originated from China, was reported on 30 January 2020. India currently has the largest number of confirmed cases in Asia.[6] As of May 2021, India has the second-highest number of confirmed cases in the world (after the United States) with nearly 20 million reported cases of COVID-19 infection and 226,188 deaths as of 5 May 2021.[7][8]
The first cases of COVID-19 in India were reported in the towns of Thrissur, Alappuzha and Kasargod, all in the state of Kerala, among three Indian medical students who had returned from Wuhan.[9] Lockdowns were announced in Kerala on 23 March, and in the rest of the country on 25 March. By mid-May 2020, five cities accounted for around half of all reported cases in the country: Mumbai, Delhi, Ahmedabad, Chennai and Thane.[10]
On 10 June, India's recoveries exceeded active cases for the first time.[11] Infection rates started to drop in September, along with the number of new and active cases.[12] Daily cases peaked mid-September with over 90,000 cases reported per-day, dropping to below 15,000 in January 2021.[13]
A second wave beginning in March 2021 was much larger than the first, with shortages of vaccines, hospital beds, oxygen cylinders and other medicines in parts of the country.[13] By late April, India led the world in new and active cases. On 30 April 2021, it became the first country to report over 400,000 new cases in a 24-hour period.[14][15] Experts believe that India's figures are vastly underreported due to poor infrastructure, low testing rates, and people dying at home.[15][16][17] [18]
India began its vaccination programme on 16 January 2021, and by April was administering 4 million doses a day.[19] India has authorised the British Oxford–AstraZeneca vaccine (Covishield), the Indian BBV152 (Covaxin) vaccine, and the Russian Sputnik V vaccine for emergency use.
As of 1 May 2021, less than 2 percent of the population has been vaccinated.[20]
2020
On 12 January 2020, the WHO confirmed that a novel coronavirus was the cause of a respiratory illness in a cluster of people in Wuhan, Hubei, China, which was reported to the WHO on 31 December 2019.[23]
On 30 January 2020, India reported its first case of COVID-19 in Thrissur, Kerala, which rose to three cases by 3 February 2020; all were students returning from Wuhan.[24] Apart from these, no significant rise in transmissions was observed in February. On 4 March, 22 new cases were reported, including 14 infected members of an Italian tourist group.[25] Transmissions increased over the month after several people with travel history to affected countries, and their contacts, tested positive. On 12 March, a 76-year-old man, with a travel history to Saudi Arabia, became the first COVID-19 fatality of India.[26] A Sikh preacher, who had a travel history to Italy and Germany, turned into a superspreader by attending a Sikh festival in Anandpur Sahib during 10–12 March.[27][28] 27 COVID-19 cases were traced back to him.[29] Over 40,000 people in 20 villages in Punjab were quarantined on 27 March to contain the spread.[28][30]
On 31 March, a Tablighi Jamaat religious congregation event in Delhi, which had taken place earlier in March, emerged as a superspreader event, after numerous cases across the country were traced back to it. On 18 April, the Health ministry announced that 4,291 cases were directly linked to the event.[31][32] As of 4 April, about 22,000 people who came in contact with the Tablighi Jamaat missionaries had to be quarantined.[33]
On 2 May, around 4,000 stranded pilgrims returned from Hazur Sahib in Nanded, Maharashtra to Punjab. Many of them tested positive, including 27 bus drivers and conductors who had been part of the transport arrangement. By 13 May, 1,225 pilgrims had tested positive.[34][35][36]
In July 2020, it was estimated based on antibody tests that at least 57% of the inhabitants of Mumbai's slums may have been infected with COVID-19 at some point.[37]
A government panel on COVID-19 stated in October 2020 that the pandemic had peaked in India, and could come under control by February 2021.[38] This prediction was based on a mathematical simulation referred to as the "Indian Supermodel", assuming that India reaches herd immunity.[39][40][41][42] That month, a new SARS-CoV-2 variant, Lineage B.1.617, was detected in the country.[43]
2021
India began its vaccination programme on 16 January 2021.[44] On 19 January 2021, nearly a year after the first reported case in the country, Lakshadweep became the last region of India to report its first case.[45] By February 2021, daily cases had fallen to 9,000 per-day.[46][47] However, by early-April 2021, a major second wave of infections took hold in the country; on 9 April, India surpassed 1 million active cases,[48] and on 12 April, India overtook Brazil as having the second-most COVID-19 cases worldwide, behind only the United States.[49]
Multiple factors have been cited as having potentially contributed to the sudden spike in cases, including highly-infectious variants of concern such as Lineage B.1.617,[50][51][52] a lack of preparations (temporary hospitals were often dismantled after cases started to decline, and new facilities were not built),[53] and health and safety precautions being poorly-implemented or enforced during festivals (such as Holi on 29 March, and the Haridwar Kumbh Mela in April),[54][55][56][57] sporting events (such as IPL[58]), state and local elections in several states,[59][60] and in public places.[56][57] An economic slowdown put pressure on the government to lift restrictions,[61] and there had been a feeling of exceptionalism based on the hope that India's young population and childhood immunisation scheme would blunt the impact of the virus.[61] Models may have underestimated projected cases and deaths due to the under-reporting of cases in the country.[62][61]
The Haridwar Kumbh Mela was linked to at least 1,700 positive cases between 10 and 14 April alone, and 68 cases among Hindu seers between 5-14 April.[63][64] Politicians and activists have been criticised for holding rallies during the pandemic.[65][66][67][68] Due to high demand, the vaccination programme began to be hit with supply issues; exports of the Oxford–AstraZeneca vaccine were suspended in order to meet domestic demand,[69] there have been shortages of the raw materials required to manufacture vaccines domestically,[70] while hesitancy and a lack of knowledge among poorer, rural communities has also impacted the programme.[69][44][47]
By late April, India passed 2.5 million active cases and was reporting an average of 300,000 new cases and 2,000 deaths per-day. Some analysts feared this was an undercount; epidemiologist Bhramar Mukherjee has estimated that the actual death toll of the pandemic in India may be two to five times higher than the official totals.[71] On 26 April, India reported 350,000 new cases and over 2,800 deaths in one day.[72] On 30 April, India reported over 400,000 new cases and over 3,500 deaths in one day.[73]
The second wave placed a major strain on the healthcare system,[56] including an ongoing shortage of liquid medical oxygen due to unanticipated demand, delays in transport, and a lack of cryogenic tankers.[74][75][76] On 21 April, 22 COVID-19 patients who required ventilators died at a hospital in Maharashtra after an accident caused a leak in its main oxygen supply.[77][78][79] On 23 April, Modi met via videoconference with liquid oxygen suppliers, where he acknowledged the need to "provide solutions in a very short time", and acknowledged efforts such as increases in production, and the use of rail (with the Indian Railways transporting tankers via "Oxygen Express" trains)[80] and air transport to deliver oxygen supplies.[81][82][83] On 25 April, the PM CARES Fund announced that it would allocate funding to install 551 oxygen plants using pressure swing adsorption at public health facilities.[84][85]
A number of countries announced that they would provide emergency aid to India. European Union member states announced that they would send oxygen supplies, medicines and ventilators through the EU Civil Protection Mechanism.[86][87] The United Kingdom planned to send oxygen concentrators and additional ventilators. Following political pressure, the United States offered to provide personal protective equipment and to lift export controls on vaccines and their materials in order to send raw materials for producing the Oxford–AstraZeneca vaccine.[88][50][89] This was the first time in 16 years that India started accepting gifts, donations and aid from foreign nations, including China.[90][91][92] Head of the U.S. National Institute of Allergy and Infectious Diseases (NIAID) Anthony Fauci stated that the country had not ruled out sending supplies of the AstraZeneca vaccine—which has not yet been approved in the U.S.—to India.[93]
Health care and testing
The Union Health Ministry's war room and policy making team in New Delhi decide how coronavirus should be tackled in the country, and consists of the ministry's Emergency Medical Response Unit, the Central Surveillance Unit (IDSP), the National Centre for Disease Control (NCDC) and experts from three government hospitals.[96] In March 2020, India's strategy was focused on cluster-containment, similar to how India contained previous epidemics, as well as "breaking the chain of transmission".[96][97][98] 52 labs were named capable of virus testing by 13 March.[99]
On 14 March 2020, scientists at the National Institute of Virology isolated a strain of the novel coronavirus. India was the fifth country to successfully obtain a pure sample of the virus, after China, Japan, Thailand and the US.[100] The Indian Council of Medical Research (ICMR) said that isolation of the virus will help towards expediting the development of drugs, vaccines and rapid diagnostic kits in the country.[101]
NIV has shared two SARS-CoV-2 genome sequences with GISAID.[102] On 16 April, China sent 650,000 testing kits to India[103] but their use was discontinued in view of a very low accuracy (of just 5.4%).[104] In May, the National Institute of Virology introduced another antibody test kit ELISA for rapid testing, capable of processing 90 samples in a single run of 2.5 hours.[105]
Initial testing
Initially, the labs tested samples only from those with a travel history to 12 countries designated as high-risk, or those who had come in contact with anyone testing positive for the coronavirus, or showing symptoms as per the government guidelines.[106][107] On 20 March 2020, the government decided to also include all pneumonia cases, regardless of travel or contact history after the country saw a sharp increase in the number of cases.[108] The first and second confirmatory tests for the virus has been made free by the government.[109] On 9 April, ICMR further revised the testing strategy and allowed testing of the people showing symptoms for a week in the hotspot areas of the country, regardless of travel history or local contact to a patient.[110]
The Ministry of Health said that only 10 per cent of test capacity had been used per day till 15 March 2020,[109] claiming that the number of tests was enough. However experts thought they were not, saying that community transmission may go undetected without adequate testing.[111] They also wanted to add more testing centres by including private laboratories.[111][107] In mid-March the government authorised accredited private labs to test for the virus.[112]
Expansion of tests
On 17 March 2020, the Union Ministry of Health decided to allow private pathology labs to test for COVID-19. The ministry official claimed that by allowing private labs, the work of testing can be doubled. The ministry said that National Accreditation Board for Testing and Calibration Laboratories (NABL) accredited laboratories may soon be allowed.[113] Once set up, a person could get a COVID-19 test at a private lab after a qualified physician in a government facility recommended it.[114] The ICMR has appealed to the private labs to offer the tests for free as the government labs do.[113]
On 18 March, a top health ministry official said that Roche Diagnostics, a Swiss company, has been given Food and Drug Administration (FDA) emergency approval to conduct tests for Covid-19. The Indian regulator gave them a licence to conduct diagnostic tests of the virus on 17 March.[115] At the end of March 2020 the government also issued guidelines to cap the cost of sample testing by private labs at ₹4,500.[116]
On 19 March, Ramanan Laxminarayan, director of the Center for Disease Dynamics, Economics & Policy stated that India could be facing a "tsunami of cases within a few weeks" as testing increases and the reason for the low number of confirmed cases currently is due to under-testing. He also said that according to mathematical models applied in the US or UK at least 20%–60% of the population will be affected. Applying the same models in India means that at the lower end of the estimate there could be 300 million cases of which 4–8 million could be severe.[117]
111 additional labs for testing became functional on 21 March.[118] On 24 March, Pune-based molecular diagnostic company Mylab Discovery Solutions became the first Indian company to have received validation for its RT-PCR tests from the National Institute of Virology and the Indian Council of Medical Research (ICMR). The test takes 2.5 hours and the company is looking to price it at around ₹1,200 (US$17), or Rs 80,000 for a 100 test kit.[119][120] In April, Institute of Genomics and Integrative Biology of Delhi had developed low cost paper-strip test that could detect COVID-19 within an hour. Each test would cost ₹500 (US$7.00).[121] On 13 April, ICMR advised pool testing in the low infection areas with a positivity rate less than 2% to increase the capacity of the testing and save resources. In this process maximum five samples are tested at once and samples are tested individually only if a pool tests positive.[122]
On 16 April 2020, 650,000 rapid antibody test and RNA extraction kits were dispatched from China, and over 2 million kits were to be sent in next 15 days.[104] On 21 April, Health department of West Bengal alleged that large number of testing kits supplied by ICMR-NICED (National Institute of Cholera and Enteric Diseases) were giving inconclusive results. ICMR-NICED admitted that there was problem in the kits and said that they are addressing the issue.[123] While Rajasthan stopped using rapid testing kits as they were giving low accuracy of 5.4% in compared to expected 90% accuracy.[124] Later, ICMR advised all states to stop using rapid testing kits for next two days until their on-ground teams validates these kits.[125] Rapid antibody test kits were put on hold till further notice. The Chinese manufactures of the rapid testing kits said that the testing kits were approved by ICMR and the problem is not with the kits but with the way they were being used. However, Chinese manufacturers promised to cooperate with Indian authorities to resolve the issue.[126][127] Amid this, ICMR asked states to return the faulty kits which will be sent back to the Chinese suppliers and cancelled the order of all remaining kits.[128][129][130]
Testing community transmission
Testing for community transmission began on 15 March. 65 laboratories of the Department of Health Research and the Indian Council of Medical Research (DHR-ICMR) have started testing random samples of people who exhibit flu-like symptoms and samples from patients without any travel history or contact with infected persons.[131][132] As of 18 March, no evidence of community transmission was found after results of 500 random samples tested negative.[133]
Between 15 February and 2 April, 5,911 SARI (Severe Acute Respiratory Illnesses) patients were tested throughout the country of which, 104 tested positive (1.8%) in 20 states and union territories. About 40% of the identified patients did not have travel history or any history of contact with a positive patient.[134] The ICMR advised to prioritize containment in the 36 districts of 15 states which had reported positive cases among SARI patients.[135] By the third quarter of the year, India had attained the highest number of daily tests in the world.[136]
During the second wave in 2021, testing did not keep up with the growing number of cases. Test positivity increased from 2% on March 1 to 22% on May 1.[137]
Research and treatment
In Rajasthan, a combination of anti-malaria, anti-swine flu and anti-HIV drugs resulted in the recovery of three patients in March 2020.[138] In the same month, the Indian Institute of Chemical Technology, the Council of Scientific and Industrial Research (CSIR) and Cipla launched a joint venture to develop anti-COVID-19 drugs.[139] Another Indian firm, Stempeutics, announced plans to introduce a stem cell-based agent for treating critical COVID-19 patients.[140] In April, funds for a number of preventive agents were released to initiate research.[141][142]
On 23 March, the National Task Force for COVID-19 constituted by the ICMR recommended the use of hydroxychloroquine for the treatment of high-risk cases.[143]
According to estimates, in March 2020 India had around 40,000 ventilators, of which 8,432 are with the public sector.[144] Various Indian PSUs, firms and startups, including DRDO and ISRO, have since repurposed their production lines to manufacture general PPEs, full body suits and ventilators. They are also designing low-cost or mobile medical equipment.[145][146][147][148]
The focus was to increase the production of low-cost, compact and portable ventilators that could cater to multiple patients at a time. This led to the creation of some of the world's smallest and cheapest ventilators.[149]
The government aims to double the current capacity of ventilators by June 2020 with the assistance from PSUs. The government has also requested major private automakers to explore the possibility of manufacturing ventilators at their plants.[150] Maruti Suzuki, in collaboration with AgVa Healthcare, will supply 10,000 ventilators till end of the May.[151] From nil in near past, India was producing around 200,000 PPE kits and 250,000 N95 masks per day in May 2020.[152] By the second half of the month, India was the world's second largest producer of PPE body coveralls.[153]
The Centre for Cellular and Molecular Biology has been working on genome sequencing of COVID-19.[154] In May, CCMB started a partnership with a private company Eyestem Research to grow novel coronavirus strain in human lung epithelial cells for research and trials of anti-viral drugs.[155]
On 12 April, the ICMR invited health institutions and hospitals to participate in trials of convalescent plasma therapy and plasma exchange therapy. Later, the ICMR submitted a list of such institutes to the DCGI to start trials,[156] which the DCGI approved.[157] Several states were allowed by ICMR to start clinical trials of the plasma therapy.[158] In Delhi, a 49-year-old man who was on ventilator support became the first patient in the country, who recovered through plasma therapy in April.[159]
Delhi CM Arvind Kejriwal said that the initial results of the plasma therapy treatment on four patients gave positive and encouraging results, adding that they had decided to conduct it on three more patients.[160] However, the ICMR later stated that there is no robust evidence to support convalescent plasma therapy as a routine therapy, describing it is as an emerging and experimental therapy. It has some risks, which include life-threatening allergies and lung injuries. The ICMR have since started multi-centre clinical trials to ensure the treatment's safety and efficacy in treating COVID-19 patients across the country.[161]
In June 2020, India approved the repurposing of a generic version of the antiviral medication favipiravir, manufactured by Glenmark Pharmaceuticals under the branding "FabiFlu" for the treatment of mild-to-moderate COVID-19 symptoms.[162] India later approved generic versions by Cipla and the Indian Institute of Chemical Technology, Jenburkt, and Lupin Limited at lower costs than FabiFlu.[163][164]
On 23 April 2021, Cadila Healthcare received an emergency authorisation to repurpose Peginterferon alfa-2b, a medication used to treat hepatitis C, as a treatment for moderate COVID-19 in adults.[165] In July 2020, the Indian firm Biocon received emergency authorisation for the use of the repurposed drug Itolizumab in treatments for chronic plaque psoriasis, one of the symptoms of the disease.[166]
Vaccination
India's Serum Institute of India licensed Oxford–AstraZeneca vaccine even before it was approved and built capacity to make 1.5–2.5 billion doses per year.[167] On 1 January 2021, the Drug Controller General of India granted an emergency use authorisation for the vaccine, which was branded "Covishield" for domestic use.[168][169] By this time, the company had stockpiled 50 million doses, but well short of its own target of 400 million.[168][167] The Government of India ordered 21 million doses to be delivered by February, but the company said no indication of any further orders were given.[20] So the company began to export the remaining stocks.[167]
In March, after India saw a surge in COVID-19 cases, the Government put a block on all vaccine exports, and ordered 110 million doses from the Serum Institute.[20] The company aims to produce 100 million doses per month, but, by May 2021, the production capacity was only 60–70 million doses.[170][171]
In January, India also approved BBV152 (Covaxin), a domestic vaccine developed by Bharat Biotech in association with the Indian Council of Medical Research and National Institute of Virology.[172] This approval was met with some concern, as the vaccine had not then completed phase 3 trials.[173] Due to this status, those receiving Covaxin were required to sign a consent form,[174] while some states chose to relegate Covaxin to a "buffer stock" and primarily distribute the Oxford–AstraZeneca vaccine.[175]
In April 2021, India approved the Russian Sputnik V vaccine and awarded emergency use authorisation to Dr. Reddy's Laboratories.[44][176] Several Indian companies have lined up to manufacture Sputnik V in India, to the tune of 850 million doses.[177][178] But the initial shipment of 150 million Sputnik V doses came from Russia, on 1 May.[179][180]
India officially launched its vaccination program on 16 January. Over 160,000 doses were administered on the first day.[181] By early May, it was reported that 160 million doses had been administered, and 30 million people had received two doses.[171] On 1 May 2021, the country began to offer vaccines to all residents 18 and over. Some states were unable to begin vaccination on the day due to shortage of vaccination supplies.[182] Critics viewed this as a politcal decision because the requisite vaccine supplies for this range of population were simply not available.[171]
Source:- https://en.wikipedia.org/wiki/COVID-19_pandemic_in_India#:~:text=The%20COVID%2D19%20pandemic%20in,reported%20on%2030%20January%202020.
How to protect yourself, your family and community from Coronavirus?
Dr Naresh Trehan's 5 Tips To Protect Yourself, Your Family And Community Post Lockdown
A third Covid-19 wave is inevitable but the timing could not be predicted, the Centre said on Wednesday. “Phase 3 is inevitable, given the levels at which the virus is circulating. But it is not clear at what time scale this will occur.
Hopefully when it occurs, we would be prepared for the virus,” Said principal scientific advisor K Vijay Raghavan.
No comments:
Post a Comment